Evolus Inc (EVL.SG)
| Previous close | 10.60 |
| Open | 10.40 |
| Bid | 10.40 x 0 |
| Ask | 10.70 x 0 |
| Day's range | 10.40 - 10.50 |
| 52-week range | 6.40 - 14.20 |
| Volume | |
| Avg. volume | 99 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Evolus Broadens International Presence with Launch of Nuceiva® (botulinum toxin type A) in Spain
NEWPORT BEACH, Calif., June 12, 2024--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company focused on building an aesthetic portfolio, has commercially launched Nuceiva® (botulinum toxin type A) in Spain. The product is now available for direct order and delivery to Spanish medical aesthetics healthcare professionals.
- Business Wire
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWPORT BEACH, Calif., June 07, 2024--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of non-qualified stock options to purchase an aggregate of 30,778 shares of Evolus and an aggregate of 29,546 restricted stock units (RSUs) of the company’s common stock to 9 newly hired non-executive employees of the company. The awards were approved by the compensation committee of the company’s board of dir
- Business Wire
Evolus Announces Positive Data from Pivotal Trial for First Two Evolysse™ Dermal Filler Products at 2024 SCALE Meeting
NEWPORT BEACH, Calif., May 20, 2024--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced positive topline results from a U.S. pivotal nasolabial fold (NLF) study of dermal filler products Evolysse™ Lift and Smooth. Data were presented at the 2024 SCALE Meeting on May 17, 2024, in Nashville.
